

## **IPSOGEN announces CE Marking of its M-bcr FusionQuant™ assay**

Marseille, France, February 16, 2004 - **IPSOGEN SAS** (Marseille, FR) today announced that it has registered with AFSSAPS, the French regulatory health care body, the M-bcr FusionQuant™ product in compliance with the European Directive 98/79 regulating In Vitro Diagnostic Medical Devices.

"Our M-bcr FusionQuant product is the first commercially available IVD assay in Europe for the quantification of the BCR-ABL gene, an acquired chromosomal abnormality occurring in about 90-95% of patients with Chronic Myeloid Leukaemia. The assay can now be utilised as a validated, standardised diagnostic tool in clinical centres in full compliance with the IVD Directive said Vincent Fert, President and CEO of IPSOGEN. "In addition this compliance represents significant improvement for leukaemia patients treated with Gleevec®, a small molecule antagonist of the tyrosine kinase activity of BCR-ABL. These patients can now benefit from the ultra sensitive, standardised FusionQuant technology that will improve the therapeutic follow-up of their disease" adds Vincent Fert.

### **About IPSOGEN**

IPSOGEN is an emerging biotechnology company utilising advanced technologies to analyse gene expression and to improve the disease management of cancers. IPSOGEN addresses two main markets : (i) The molecular diagnosis of cancer (i.e; leukaemia, lymphomas, breast cancer) to provide innovative diagnostic tools to clinical centers; (ii) The optimisation of discovery and development of anti cancer drugs, to provide pharmaceutical companies with high value information at the pre-clinical and clinical stages, and accelerate drug development through biomarker discovery and validation. Headquartered in Marseille, France, IPSOGEN has global partnerships and markets its product worldwide.

*This press release contains "forward-looking statements" as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Ipsogen SAS does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Ipsogen SAS, among others, the extent to which Ipsogen's technology platform can be used in large scale gene expression analysis, uncertainty of market acceptance of Ipsogen's technologies or ability to compete against existing technologies.*

### **CONTACTS**

IPSOGEN: Vincent Fert, CEO - Tel +33 (0)4 91293091- fert@ipsogen.com